Other examples include PF-06747143, a humanized IgG1 anti-CXCR4 antibody from Pfizer [101, 102], LY2624587, a recombinant humanized anti-CXCR4 monoclonal antibody from Eli Lilly [103] and F50067 (Hz515H7), an IgG1 monoclonal antibody developed by Pierre Fabre SA, that have been primarily studied in hematologic malignancies with early-stage clinical trials [104]. The gene discussed is CXCR4; the disease is hematologic disorder.